Artificial Heart Frontiers Program (AHFP)

Name

Artificial Heart Frontiers Program (AHFP)

Legal name

Monash University (operating the Artificial Heart Frontiers Program)

Website

https://ahfp.org.au

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Implantable Cardiac Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Scientific Research and Development Services (5417)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

Keywords

• Artificial heart devices
• Implantable cardiac devices
• Heart failure treatment
• Medical device research
• Cardiac assist devices

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Government Research Grants: Primary funding from Australian Federal Government through the Medical Research Future Fund (MRFF) Frontier Health and Medical Research initiative. Federal government committed $50 million to develop artificial heart devices.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

AHFP is a multidisciplinary research consortium developing a suite of next-generation implantable artificial heart devices constructed from titanium and magnets. The devices are designed for long-term use to support patients with end-stage heart failure, including those awaiting transplants and non-transplant candidates, and are being engineered to be compatible with both pediatric and adult patients. The program is preparing for human clinical trials as a step toward eventual commercialization.

Product overview

The Artificial Heart Frontiers Program is a multidisciplinary research consortium led by Monash University developing a suite of next-generation implantable heart devices for patients with heart failure. The program focuses on creating artificial heart technology that enables patients to live active lives while waiting for transplants. The core product comprises implantable heart devices constructed from titanium and magnets, representing Australia's contribution to transforming cardiac care globally.

Differentiator

Problem solved

Functional benefit

Products and services

• Next-Generation Implantable Heart Devices A suite of next-generation implantable artificial heart devices being developed by AHFP to support patients with end-stage heart failure. The devices use titanium construction and a magnetically driven pumping mechanism designed for long-term use, eliminating mechanical bearings to enhance durability. The devices are being engineered to be compatible with both pediatric and adult patients and are intended to allow patients to live active lives while awaiting transplants or as a permanent cardiac support solution.

Quantifiable outcome

• 30,000+ Australians diagnosed with heart failure annually
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Australia-wide CollaborationscoreStrategic or Co-development PartnerThe program maintains Australia-wide collaborations with healthcare and research institutions for device development, testing, and future clinical implementation of artificial heart technologies.

Scale indicators6 records

Recent moves4 records

Expansion highlights5 records

Emerging players

• CorWave: French medtech developing next-generation LVADs using a wave-membrane pumping technology with the aim of reducing hemocomplication rates. Emerging competitor pursuing next-generation durable VAD indications overlapping with AHFP's cardiac assist focus.
• Procyrion: Developer of Aortix, a catheter-deployed circulatory support pump targeting chronic heart failure. Comparable as an emerging mechanical heart failure therapy developer with a fundamentally different but adjacent device approach.
• Jarvik Heart: Developer of continuous-flow ventricular assist devices, including the Jarvik 2000. Comparable as a long-term mechanical circulatory support developer with technology overlap in rotor and pump design.
• BrioHealth (Yuanxin Medical / MagAssist): Chinese developer of magnetically levitated total artificial hearts and VADs (e.g., CH-VAD, BrioFlow). Closely comparable technology pathway using magnetic levitation analogous to AHFP's titanium/magnetic architecture.

Broad incumbents

• Abbott: Through the HeartMate 3 left ventricular assist device (LVAD) and the legacy Thoratec franchise, Abbott dominates durable mechanical circulatory support. Competes indirectly with AHFP in the broader heart failure device market and is the most likely future strategic acquirer.
• ReliantHeart (now HeartWare/Medtronic legacy): Medtronic's HVAD system (acquired via HeartWare) was once a major long-term VAD competitor; its 2021 global withdrawal illustrates both the opportunity and the durability/complication risk in this category that AHFP must navigate.

Direct peers

• BiVACOR: Clinical-stage total artificial heart company using a magnetically levitated rotor with no bearings—architecturally the closest analog to AHFP's titanium-and-magnetic approach. Highly comparable technology and target indication.
• Carmat: European developer of a bioprosthetic total artificial heart (Aeson) intended as a bridge to transplant or destination therapy. Direct peer as a competing total artificial heart with CE marking efforts, sharing the same clinical and regulatory pathway considerations as AHFP.
• Berlin Heart: Manufacturer of the EXCOR Pediatric VAD, the primary long-term mechanical circulatory support option for children with severe heart failure. Direct peer given AHFP's pediatric-and-adult device strategy targeting a similar pediatric population.
• SynCardia Systems: Developer of the SynCardia total artificial heart (TAH), historically the only commercially available TAH. Directly comparable as a total artificial heart program targeting bridge-to-transplant, which AHFP's long-term artificial heart is designed to extend beyond.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/artificialheartfrontiers

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artificial Heart Frontiers Program (AHFP)